Table 2

Results in 37 samples tested for both MSI status and hMLH1 expression

Hyperplasia (n=13)Dysplasia (n=13)Carcinoma (n=11)
14/51/50/50/52/62/62/62-150 4/60/20/22/22-151 2/2
20/10/11/12-152 1/11/21/20/20/2
  • S, stable, L, low, H, high (microsatellite instability (MSI) status); hMLH1, loss of protein by immunohistochemistry.

  • Mutated target genes in samples tested only from patient Nos 1–3 were as follows:

  • 2-150 TGFβ-RII, IGF2R, BAX, MSH3, MSH6 in dysplasia contiguous with smaller cancer, MSH6 in dysplastic focus;

  • 2-151 TGFβR-II, IGF2R, BAX, MSH3, MSH6 in smaller cancer, MSH6 in larger cancer;

  • 2-152 BAX, MSH3.